Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indevus Pharmaceuticals has announced positive results of the ongoing phase III extension study of Supprelin LA, the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty.
Subscribe to our email newsletter
This study evaluated the two-year safety and efficacy of Supprelin LA in children who received a second implant following an initial year of therapy. The study found that Supprelin LA demonstrated continued profound hormone suppression with no escapes (breakthrough of hormones) and led to continued decreases in rates of growth, skeletal maturation and body mass index at 24 months compared to 12 months.
Gad Kletter, head of pediatric endocrinology, Swedish Medical Center, Seattle, said: “This study confirms that Supprelin LA maintains remarkable suppression of peak hormone and sex steroid levels for two years in children with central precocious puberty and that the removal of the first implant and insertion of the second does not influence efficacy. While the frequent dosing of traditional injections may lead to issues with long-term compliance, Supprelin LA offers patients, families and physicians a truly sustained treatment option that only requires action once a year.”